Novartis AG
Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate

Last updated:

Abstract:

The present invention provides methods of inducing differentiation of oligodendrocyte progenitor cells to a mature myelinating cell fate with a neurotransmitter receptor modulating agent. The present invention also provides methods of stimulating increased myelination in a subject in need thereof by administering said neurotransmitter receptor modulating agent. Methods of treating a subject having a demyelinating disease using a neurotransmitter receptor modulating agent are also provided.

Status:
Grant
Type:

Utility

Filling date:

8 Apr 2020

Issue date:

15 Feb 2022